An adaptive design is a clinical trial design that allows for prospectively planned modifications to one or more aspects of the trial based on accumulating data from subjects already enrolled, without undermining the trial’s validity or integrity. Adaptive designs are increasingly used across all phases of drug and biologic development, and the U.S. Food and Drug Administration finalized dedicated guidance on the topic in December 2019. This guide explains what qualifies as an adaptive design, the common types of adaptations sponsors use, what the FDA guidance covers, and the statistical and operational safeguards that make an adaptive trial defensible. Master protocols — basket, umbrella, and platform trials — are a closely related family with their own FDA guidance; the agency issued a revised draft guidance on master protocols on 22 June 2026.
What Is an Adaptive Design?
The defining feature of an adaptive design is that the modification is prospectively planned: the possible changes, the data that will trigger them, and the decision rules for making them are specified in the protocol and statistical analysis plan (SAP) before the trial begins, or before the relevant data are unblinded. This distinguishes an adaptive design from an ad hoc protocol amendment made in response to unplanned circumstances. A trial that simply changes course mid-study because enrollment is slow, or because investigators informally decide a dose looks wrong, is not an adaptive design in the regulatory sense — it is an unplanned deviation, and it carries a much higher risk of introducing bias.
Adaptive designs can be used at any phase of clinical development discussed in clinical trial phases, from early dose-finding studies through confirmatory Phase 3 trials, and they range from relatively simple (e.g., a single planned sample-size re-estimation) to highly complex, simulation-guided, Bayesian designs.
Why Sponsors Use Adaptive Designs
Sponsors adopt adaptive designs primarily for statistical and ethical efficiency. By allowing a trial to use accumulating internal data to refine its own design, adaptive approaches can:
- Reduce the number of participants exposed to a treatment arm that is performing poorly, by allowing that arm to be dropped early.
- Improve the chance of correctly identifying an effective dose or subpopulation before committing to a large confirmatory trial.
- Use resources more efficiently by adjusting sample size based on the observed treatment effect or variability rather than a fixed, conservative estimate made before any data exist.
- Shorten overall development timelines in some cases, for example by combining what would otherwise be separate Phase 2 and Phase 3 trials into a single seamless design.
These efficiencies come with a trade-off: adaptive designs are statistically and operationally more complex to plan, execute, and defend to regulators than a traditional fixed design, which is why they require more upfront statistical planning, not less.
Common Types of Adaptations
There is no single “adaptive trial” — the term covers a family of design techniques that are often combined. The most common include:
- Sample size re-estimation. The trial’s target sample size is recalculated partway through, using either blinded information (e.g., the observed variability or event rate, without unblinding treatment assignment) or unblinded information (the observed treatment effect itself), following rules set out in advance.
- Dropping arms or treatment selection. In a multi-arm trial, one or more doses or treatment arms that show insufficient efficacy or an unacceptable safety signal at a planned interim look are dropped, and the trial continues with the remaining arm(s).
- Response-adaptive randomization. The probability that a new participant is assigned to a given arm changes over the course of the trial based on the outcomes observed so far, shifting allocation toward arms that appear to be performing better.
- Seamless Phase 2/3 designs. A single trial protocol combines what would traditionally be a separate dose-finding (Phase 2) study and a confirmatory (Phase 3) study, using an interim analysis to select the dose or population that carries forward into the confirmatory portion, with data from both stages potentially contributing to the final analysis.
- Group sequential designs. The trial is planned with a fixed number of interim analyses at which it can stop early for efficacy, futility, or safety, using statistical stopping boundaries (e.g., O’Brien-Fleming or Pocock-type boundaries) set in advance to control the overall Type I error rate.
- Adaptive platform trials. A standing trial infrastructure evaluates multiple interventions against a shared control over time, with arms added or dropped as evidence accumulates — a design used in several large multi-arm infectious disease and oncology programs.
The FDA Guidance on Adaptive Designs
The FDA issued draft guidance on adaptive designs for drug and biologic trials in 2018 and finalized it in the Federal Register in December 2019 as “Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry.” The guidance defines an adaptive design in essentially the terms used above — a prospectively planned opportunity for modification based on accumulating trial data — and lays out the agency’s expectations for how sponsors should plan, conduct, and report adaptive trials, including designs that use Bayesian methods or that are complex enough to require simulation studies to characterize their statistical properties.
Key themes in the final guidance include the need for a clear, pre-specified adaptation plan; adequate control of the trial’s overall Type I error rate across all planned adaptations and analyses; maintenance of trial integrity, including appropriate limits on who has access to unblinded interim data; and, for more complex or novel adaptive designs, early engagement with the FDA review division (for example through a pre-IND or other formal meeting) before the trial begins. The guidance gave sponsors some added flexibility, relative to the 2018 draft, regarding how much detail must be pre-specified for certain Bayesian adaptive designs, while still requiring that the overall statistical approach be defined and justified in advance.
Key Considerations for a Defensible Adaptive Design
Several safeguards separate a scientifically and regulatorily defensible adaptive trial from one that simply changes its design opportunistically:
- Type I error control. Because an adaptive design allows for multiple looks at the data and potential design changes, the statistical analysis plan must show how the overall false-positive (Type I error) rate is controlled across all planned interim analyses and adaptations, not just at the final analysis.
- Pre-specification. The adaptation rules, decision criteria, and statistical methods must be written into the protocol and SAP, and finalized, before the data that will inform the adaptation are unblinded. Rules added or changed after seeing unblinded results undermine the trial’s credibility.
- Maintaining blinding and minimizing operational bias. Access to unblinded interim results is typically restricted to an independent group, so that the study team, investigators, and sponsor personnel running the trial remain unaware of accumulating results and cannot consciously or unconsciously alter enrollment, assessment, or other trial conduct in response.
- Independent oversight of interim looks. Interim analyses in adaptive trials are generally reviewed by an independent statistician or an independent Data Safety Monitoring Board (DSMB), which applies the pre-specified decision rules and reports only the resulting recommendation (e.g., continue, modify, or stop) back to the sponsor, keeping the underlying unblinded data separate from those running the trial day to day.
- Early regulatory engagement. For adaptive designs beyond straightforward, well-established techniques, the FDA guidance recommends sponsors discuss the proposed design with the relevant review division before the trial starts, since the statistical and operational justification for a complex adaptive design is reviewed as part of the trial’s overall regulatory acceptability.
- Protocol and study oversight review. As with any trial, the adaptive design and its statistical justification are reviewed by the relevant institutional and scientific oversight bodies — see Scientific Review Committee — alongside IRB/ethics review, before enrollment begins.
Adaptive vs. Fixed (Traditional) Design
A traditional fixed design specifies the sample size, arms, randomization scheme, and analysis plan in advance and does not change them based on data observed during the trial (aside from ordinary, non-adaptive protocol amendments). An adaptive design shares that same requirement for advance planning, but prospectively builds in specific, rule-based opportunities to modify the trial based on what the accumulating data show. Fixed designs are simpler to plan, conduct, and interpret, and remain the right choice for many trials, particularly where the relevant uncertainties (effect size, variability, appropriate dose) are already well understood. Adaptive designs are generally considered when there is meaningful uncertainty at the outset that interim data could resolve, and when the added statistical and operational complexity is justified by the potential efficiency or ethical gains.
Frequently Asked Questions
What is the difference between an adaptive and a traditional fixed trial design?
A fixed design locks in its sample size, arms, and analysis plan before the trial starts and does not change them based on internal trial data. An adaptive design also plans everything in advance, but explicitly builds in pre-specified opportunities to modify aspects of the design — such as sample size, arms, or randomization ratios — based on data accumulated during the trial itself.
Does an adaptive design have to be pre-specified before the trial starts?
Yes. The core requirement of an adaptive design, per FDA guidance, is that the possible modifications, the triggering data, and the decision rules are specified in the protocol and statistical analysis plan before the trial begins, or before the relevant data are unblinded. Changes decided after seeing unblinded results are not adaptive design adaptations — they are unplanned deviations.
What is response-adaptive randomization?
Response-adaptive randomization is a technique in which the probability that a new participant is assigned to a given treatment arm changes during the trial based on the outcomes observed in participants enrolled so far, generally shifting allocation toward arms that appear to be performing better while the trial continues.
What is a seamless Phase 2/3 trial?
A seamless Phase 2/3 trial combines a dose-finding or treatment-selection stage with a confirmatory stage in a single protocol. An interim analysis is used to select which dose, arm, or population moves forward into the confirmatory portion, and data from both stages can potentially contribute to the final analysis, rather than running two entirely separate trials in sequence.
Who reviews the interim data in an adaptive trial?
Interim, unblinded data in an adaptive trial are typically reviewed by an independent statistician or an independent Data Safety Monitoring Board (DSMB) that applies the pre-specified decision rules and communicates only the resulting recommendation to the sponsor, rather than the underlying unblinded results — this separation is intended to protect the trial from operational bias and preserve its scientific integrity.
For related concepts, see the clinical research pillar page and the guide to clinical trial phases.
